Owner Scorecard


← All companies ← BGIN Manual BGSI → ← BCYC Pharmaceuticals BHC →

BGM, BGM Group Ltd.

Pharmaceuticals consumer brand Cyclical

Revenue is Diversified Pharmaceutical and Allied Products (62%), Insurance Business (29%) and AI Solutions (9%).

Latest annual: FY2025 20-F · US listing is the ordinary share
BGM · BGM Group Ltd.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$38M
+51.1% YoY · −5% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $38M 5-yr avg $46M
Gross margin 17% 5-yr avg 11%
Operating margin −33.2% 5-yr avg −6.7%
ROIC −3% 5-yr avg −0%
Owner-earnings margin −10% 5-yr avg 1%
Free cash flow margin −10% 5-yr avg 1%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
Situation
Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
What moves the needle
Gross margin has run about 16% and operating margin about 3.7% through the cycle, a thin spread that turns the result on volume and the cost of what it sells far more than on the price it sets. The margin is cyclical, swinging between −33% and 13% over the years, so the through-cycle figure carries more than any single year — and the balance sheet at the trough more than the peak. Inventory runs near 22% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median 5%, above 15% in 2 of 7 years). Owner earnings, the cash-based check, have been thin too. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 20-F →

Diversified Pharmaceutical and Allied Products is 62% of revenue, with Insurance Business the other meaningful segment at 29%.

Revenue by reportable segment, FY2025
  • Diversified Pharmaceutical and Allied Products62%$24M
  • Insurance Business29%$11M
  • AI Solutions9%$3M
  • International Markets0%$0

From the segment footnote of the company's own 20-F. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2018–2025

realized figures from each filing · older years to the left
2018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMSep 2025
Income statement
$50M$46M$50M$57M$65M$46M$25M$38M$38MRevenueRevenue
$8M$10M$8M$6M$6M$2M$4M$6M$6MGross profitGross prof.
16%21%15%10%10%4%16%17%17%Gross marginGross mgn
$6M$6M$5M$2M$2M($3M)($564K)($13M)($13M)Operating incomeOp. inc.
11.9%13.4%9.6%4.2%3.2%−5.6%−2.2%−33.2%−33.2%Operating marginOp. mgn
$5M$6M$5M$3M$1M($8M)($2M)($20M)($20M)Net incomeNet inc.
15%15%15%8%12%Effective tax rateTax rate
Cash flow & returns
$4M($580K)$5M$345K$13M$312K$544K($2M)($2M)Operating cash flowOp. cash
$1M$1M$1M$1M$1M$1M$1M$1M$1MDepreciationDeprec.
($2M)($8M)($970K)($4M)$10M$7M$824K$16M$16MWorking capital & otherWC & other
$1M$616K$450K$1M$2M$180K$240K$2M$2MCapexCapex
2.2%1.3%0.9%2.6%3.1%0.4%1.0%4.1%4.1%Capex / revenueCapex/rev
$3M($1M)$5M($1M)$11M$132K$304K($4M)($4M)Owner earningsOwner earn.
6.6%−2.6%9.2%−2.0%16.4%0.3%1.2%−10.4%−10.4%Owner earnings marginOE mgn
$3M($1M)$5M($1M)$11M$132K$304K($4M)($4M)Free cash flowFCF
6.6%−2.6%9.2%−2.0%16.4%0.3%1.2%−10.4%−10.4%Free cash flow marginFCF mgn
$734K$2M$2MDividends paidDiv. paid
34%29%5%5%-6%-1%-3%-3%ROICROIC
30%19%6%3%-19%-4%-5%-5%Return on equityROE
Balance sheet
$5M$12M$10M$14M$8M$10M$10M$11MCash & investmentsCash+inv
$604K$1M$2M$815K$2M$2M$4M$4MReceivablesReceiv.
$13M$12M$12M$9M$5M$5M$20M$20MInventoryInvent.
$4M$4M$7M$5M$4M$4M$7M$7MAccounts payablePayables
$10M$9M$8M$4M$3M$2M$18M$18MOperating working capitalOper. WC
$25M$38M$40M$30M$35M$30M$52M$52MCurrent assetsCur. assets
$12M$18M$18M$9M$7M$9M$42M$42MCurrent liabilitiesCur. liab.
2.1×2.0×2.2×3.3×5.2×3.4×1.2×1.2×Current ratioCurr. ratio
$8M$7M$9M$10M$10MNet PP&ENet PP&E
$35M$48M$75M$65M$51M$53M$434M$434MTotal assetsAssets
($5M)($12M)($10M)($14M)($8M)($10M)($10M)($11M)Net debt / (cash)Net debt
27.6×27.6×19.8×41.4×-218.2×Interest coverageInt. cov.
$20M$26M$55M$53M$43M$43M$391M$391MShareholders’ equityEquity
Per share
450M450M450M511M108M108M108M113M201MShares out (diluted)Shares
$0.11$0.10$0.11$0.11$0.60$0.43$0.23$0.33$0.19Revenue / shareRev/sh
$0.01$0.01$0.01$0.01$0.01$-0.07$-0.01$-0.18$-0.10EPS (diluted)EPS
$0.01$-0.00$0.01$-0.00$0.10$0.00$0.00$-0.03$-0.02Owner earnings / shareOE/sh
$0.01$-0.00$0.01$-0.00$0.10$0.00$0.00$-0.03$-0.02Free cash flow / shareFCF/sh
$0.00$0.02$0.01Dividends / shareDiv/sh
$0.00$0.00$0.00$0.00$0.02$0.00$0.00$0.01$0.01Cap. spending / shareCapex/sh
$0.04$0.06$0.11$0.49$0.39$0.39$3.45$1.95Book value / shareBVPS

The diluted share count moved ×1/4.72 into 2022 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Share counts before 2025 are restated ×15 for a stock split, so per-share figures sit on one basis.

The diluted share count moved ×1.77 into TTM — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
7-yr5-yr
Revenue / share+16.9%/yr+24.7%/yr
Dividends / share+58.8%/yr (5-yr)+58.8%/yr
Capital spending / share+27.8%/yr+69.1%/yr
Book value / share+106.7%/yr (6-yr)+126.4%/yr

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2018FY2024

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned a $20M loss into ($4M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2025FY2024FY2023FY2022FY2021
Reported net income($20M)($2M)($8M)$1M$3M
Depreciation & amortizationnon-cash charge added back+$1M+$1M+$1M+$1M+$1M
Working capital & othertiming of cash in and out, other non-cash items+$16M+$824K+$7M+$10M−$4M
Cash from operations($2M)$544K$312K$13M$345K
Capital expenditurecash put back in to keep running and to grow−$2M−$240K−$180K−$2M−$1M
Owner earnings($4M)$304K$132K$11M($1M)
Owner-earnings marginowner earnings ÷ revenue-10%1%0%16%-2%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 20-F · source on SEC EDGAR →
Material weakness in financial controls
“To remedy our identified material weakness identified to date, we have implemented and plan to implement a number of measures to strengthen our internal control over financial reporting, including (i) recruiting more financial reporting and accounting…”

The figures below are only as sound as the controls that produced them. read the note →

Will it survive?

  • Does not cover its interest
    Operating income ($13M) ÷ interest expense $58K
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash, debt-free
    Cash $10M + ST investments $1M − debt $0
    What this means

    Cash and short-term investments exceed every dollar of debt by $11M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 41 + DIO 232 − DPO 76 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Not enough data
    Industry peers: median -43%
    What this means

    The filing data didn't include the inputs for this check.

  • Thin through the cycle
    8-yr median margin, range -10%–16%; latest ($4M) = operating cash ($2M) − maintenance capex $2M
    Industry peers: median -62%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -10% of revenue this year, a 1% median across 8 years.

  • Loss, and burning cash
    Net income ($20M) · cash from operations ($2M)

    In the filing’s words The filing discloses a material weakness in its financial controls — the reported numbers here, and the record built on them, are only as reliable as the controls that produced them.

    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • No surplus to allocate
    What this means

    The business didn't generate positive Owner Earnings this year, so any distributions came from the balance sheet or borrowing, not from operations.

  • Investing or harvesting? 1.07×
    Maintaining
    Capex $2M ÷ depreciation $1M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 0 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $38M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Miss
    Current ratio ≥ 2× · 1.24×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Earnings stability Miss
    A profit every year (8-yr record) · 3 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · 2 of 8 yrs
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth Miss
    Earnings +33% over the record · −286%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.09/share (latest year $-0.18), the averaged base the calculator's gate runs on, and book value is $3.45/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2018–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 5 of 8
    What this means

    Lost money in 3 year(s), look at what happened there before trusting the average.

  • Operating margin 12% → −14% (3-yr avg ends)
    What this means

    Through the cycle the operating margin slipped — about 12% early to −14% lately, median 3% — competition or costs are biting in.

  • Worst year 2025 · −33.2% op. margin
    What this means

    Operations went underwater in 2025, understand why before trusting the good years.

  • Dividend record rising
    What this means

    Paid and raised the dividend across the record, the continuity Graham prized.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Sep 30, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$52M
  • Cash & short-term investments$11M
  • Receivables$4M
  • Inventory$20M
  • Other current assets$16M
Current liabilities$42M
  • Accounts payable$7M
  • Other current liabilities$35M
Current ratio1.24×all current assets ÷ what's due · Graham looked for 2×
Quick ratio0.76×stricter: inventory excluded
Cash ratio0.26×strictest: cash alone against what's due
Working capital$10Mthe cushion left after near-term bills
Cash runway2.7 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Deeper floors
Tangible book value$36Mequity stripped of goodwill & intangibles
Net current asset value$10MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$241K$241K of it operating leases
Deferred revenue$3Mcustomer cash collected before delivery; operating float

From the company's latest filing.

How the cash was used, 2018–2025

Over the record, the business generated $20M of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested$8M · 38%
  • Dividends$3M · 12%
  • Retained (debt / cash)$10M · 50%
  • Returned to owners$3M

    20% of the owner earnings the business produced over the span, $3M as dividends and $0 as buybacks.

  • Net change in share count−55.4%

    The diluted count fell from 450M to 201M, so the buybacks outran the stock issued to staff.

  • Dividend record$0.02/sh

    Paid in 2 of the years on record, the per-share dividend growing about 911% a year. It was never cut over the span.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Acquisitions & goodwill

from the balance sheet & the 8-year cash-flow record

Goodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.

Goodwill & intangibles$355M82% of all assets; the premium carried on the balance sheet for businesses acquired
Against book equity90%goodwill is this share of book equity; the rest is the company’s own retained and paid-in capital
Cash spent acquiring$0over 8 years buying other businesses, against $8M of capital spent building over the 8-year record

None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.

Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend summed across the company's full tagged history, write-downs across the 8-year record, from the company's own filings.

What an owner would ask, FY2025

read the 10-K →
  • How much of the revenue rides on one buyer?
    ≈$6M · 16% of revenue on the largest customers (TTM)
    “For the fiscal year ended September 30, 2025, two customers represented approximately 16% and 11% of the sales of the WFOE and the VIE and its subsidiaries, respectively.”verify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
PTGXProtagonist Therapeutics Inc.$46M-207.1%-56%-141%
SEPNSepterna Inc.$46M612.8%2y-28%2y-12968%2y
AQSTAquestive Therapeutics Inc.$45M60%-72.6%-286%1y-62%
WVEWave Life Sciences Ltd.$43M-310.1%-219%
NBTXNanobiotix S.A.$38M-53.6%-70%
BGMBGM Group Ltd.$38M16%3.7%5%1%
BHSTBioHarvest Sciences Inc.$35M55%-27.7%-182%1y-32%
PREPrenetics Global Limited$31M40%-238.7%-29%-6%
Group median48%-63.1%-43%-66%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. BGM Group Ltd.'s US listing is the ordinary share itself. The record tables elsewhere on this page remain as filed.

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what BGM Group Ltd. has delivered.

BGM Group Ltd.’s latest year shows negative owner earnings, a cyclical trough. So the tool opens on the through-cycle base, the cash it would earn at rest; clear the toggle below to read the latest year exactly as reported.

$

Through the cycle, BGM Group Ltd. earns about $284K on its 0.7% median owner-earnings margin. This year’s −10.4% margin runs below that; the reported figure may understate a lean year. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.71% 10-year Treasury (Aug 18, 2026) + 4.29 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth, delivered
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.71%, as of Aug 18, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings ($4M) on 113M shares outstanding (a weighted average, the only count this filer tags); net cash $11M. The if-converted diluted count is 201M, 77% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base opens on the through-cycle figure (the latest year sits off the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "BGM Group Ltd. (BGM), the owner's record," https://ownerscorecard.com/c/BGM, data as of 2026-08-17.

Manual order: ← BGIN its page in the Manual BGSI →

Industry order: ← BCYC the Pharmaceuticals chapter BHC →